Cargando…

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting

Poly(ADP-ribose) polymerases have shown true promise in early clinical studies due to reported activity in BRCA-associated cancers. PARP inhibitors may represent a potentially important new class of chemotherapeutic agents directed at targeting cancers with defective DNA-damage repair. In order to w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dziadkowiec, Karolina N., Gąsiorowska, Emilia, Nowak-Markwitz, Ewa, Jankowska, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2017
Materias:	Review Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327624/ https://www.ncbi.nlm.nih.gov/pubmed/28250726 http://dx.doi.org/10.5114/pm.2016.65667

Ejemplares similares

Assessment of gynecological and lifestyle-related risk factors of ovarian cancer
por: Abdulaziz, Gazala, et al.
Publicado: (2021)

CGB and GNRH1 expression analysis as a method of tumor cells metastatic spread detection in patients with gynecological malignances
por: Andrusiewicz, Mirosław, et al.
Publicado: (2011)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival
por: Shao, Fengping, et al.
Publicado: (2021)

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2023)

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
por: Dilmac, Sayra, et al.
Publicado: (2023)

Human Epididymis Protein 4 (HE4) Reference Limits in Polish Population of Healthy Women, Pregnant Women, and Women with Benign Ovarian Tumors
por: Gasiorowska, Emilia, et al.
Publicado: (2019)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
por: Petrelli, Annalisa, et al.
Publicado: (2023)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
por: Faraoni, Isabella, et al.
Publicado: (2018)

Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors
por: Imyanitov, Evgeny, et al.
Publicado: (2021)

TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status
por: Ben Khaled, Najib, et al.
Publicado: (2022)

Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia
por: Oei, Arlene L., et al.
Publicado: (2017)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
por: Zatreanu, Diana, et al.
Publicado: (2021)

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
por: Nesic, Ksenija, et al.
Publicado: (2023)

The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1(+/-) lymphoblastoid cells
por: Bourton, Emma C., et al.
Publicado: (2017)

Human Chorionic Gonadotropin Beta Subunit Genes CGB1 and CGB2 are Transcriptionally Active in Ovarian Cancer
por: Kubiczak, Marta, et al.
Publicado: (2013)

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition
por: Aziz, Diar, et al.
Publicado: (2021)

PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers
por: Sokol, Ethan S., et al.
Publicado: (2022)

Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
por: Wang, Chuanlin, et al.
Publicado: (2022)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
por: Tacconi, Eliana MC, et al.
Publicado: (2019)

Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers
por: Sun, Chong-kui, et al.
Publicado: (2014)

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
por: Rafii, Saeed, et al.
Publicado: (2017)

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
por: Reisländer, Timo, et al.
Publicado: (2019)

Roles of the PARP Inhibitor in BRCA1 and BRCA2 Pathogenic Mutated Metastatic Prostate Cancer: Direct Functions and Modification of the Tumor Microenvironment
por: Inoue, Takahiro, et al.
Publicado: (2023)

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022)

PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
por: Rose, Maddison, et al.
Publicado: (2020)

Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes
por: Onji, Hiroshi, et al.
Publicado: (2022)

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
por: Konecny, G E, et al.
Publicado: (2016)

BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
por: Pishvaian, Michael J, et al.
Publicado: (2017)

Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation
por: Shammas, Natalie, et al.
Publicado: (2022)

Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights
por: Ragupathi, Ashwin, et al.
Publicado: (2023)

PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
por: Frizzell, Kristine M, et al.
Publicado: (2009)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
por: Keung, Man Yee, et al.
Publicado: (2020)

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
por: Menezes, Maria Clara Saad, et al.
Publicado: (2022)

Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer
por: Li, Peng, et al.
Publicado: (2023)

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours
por: Ordonez, Liliana D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s8ank2e29jgmeik97njcj7nhpt